(VIANEWS) - Westamerica Bancorporation (WABC), California BanCorp (CALB), United Therapeutics Corporation (UTHR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Westamerica Bancorporation (WABC)
39.6% sales growth and 17.08% return on equity
Westamerica Bancorporation operates as a bank holding company for the Westamerica Bank that provides various banking products and services to individual and commercial customers. The company accepts various deposit products, including retail savings and checking accounts, as well as certificates of deposit. Its loan portfolio includes commercial, commercial and residential real estate, real estate construction, and consumer installment loans, as well as other loans primarily consisting of indirect automobile loans. Westamerica Bancorporation operates through 79 branch offices in 21 counties in Northern and Central California. The company was formerly known as Independent Bankshares Corporation and changed its name to Westamerica Bancorporation in 1983. Westamerica Bancorporation was founded in 1972 and is headquartered in San Rafael, California.
Earnings Per Share
As for profitability, Westamerica Bancorporation has a trailing twelve months EPS of $4.54.
PE Ratio
Westamerica Bancorporation has a trailing twelve months price to earnings ratio of 12.33. Meaning, the purchaser of the share is investing $12.33 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.08%.Moving Average
Westamerica Bancorporation is at $59.16 on its 50-day moving mean and $58.04 on its 200-day moving mean.2. California BanCorp (CALB)
24.4% sales growth and 9.46% return on equity
California BanCorp operates as the bank holding company for California Bank of Commerce that provides commercial banking services to small to medium-sized businesses and professional firms in California. It accepts various deposit products, including commercial checking, savings, and money market accounts, as well as certificates of deposit. The company also offers asset-based lending loans; standby letters of credit; construction and development loans; real estate loans, such as commercial real estate loans and other loans; small business administration (SBA) loans, including SBA 7(a) and SBA 504 loans; consumer loans, such as secured and unsecured installment loans, and revolving lines of credit; and commercial and industrial loans, including term loans, working capital, accounts receivable and inventory financing, and other business loans to the dental and veterinary industries, contractors, and emerging companies. In addition, it provides foreign exchange, treasury and cash management, and online and mobile banking services. The company operates through a network of 2 full-service branches in Contra Costa County and Santa Clara County, California, as well as 4 loan production offices in Oakland, Walnut Creek, San Jose, and Sacramento, California. California BanCorp was incorporated in 2007 and is headquartered in Oakland, California.
Earnings Per Share
As for profitability, California BanCorp has a trailing twelve months EPS of $0.81.
PE Ratio
California BanCorp has a trailing twelve months price to earnings ratio of 29.05. Meaning, the purchaser of the share is investing $29.05 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.46%.Moving Average
California BanCorp's value is under its 50-day moving average of $24.02 and above its 200-day moving average of $21.54.Annual Top and Bottom Value
California BanCorp stock was valued at $23.56 as of 00:22 EST. This is below its 52-week peak of $25.20, and well above its 52 week low of $18.51.
Sales Growth
California BanCorp has a 29.7% quarter-over-quarter sales growth and 24.4% in the following.
Volume
Today's last reported volume for California BanCorp is 48604 which is 221.41% above its average volume of 15122.
3. United Therapeutics Corporation (UTHR)
20.8% sales growth and 15.85% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Earnings per Share
United Therapeutics Corporation's trailing 12 months earnings per share (EPS) is $11.54.
PE Ratio
United Therapeutics Corporation's trailing 12-month price-to-earnings ratio is 22.68. The purchaser of the shares is therefore investing $22.68 per dollar in annual earnings.
For the 12 trailing months, the company's return-on-equity, which is a measure of the business' profitability relative to shareholders' equity, was 15.85%.Sales Growth
United Therapeutics Corporation's sales growth is 10.9% for the ongoing quarter and 20.8% for the next.
Growth Estimates Quarters
For the current quarter, the company expects to grow by 13.7% and 56.6% respectively.Yearly Top and Bottom Value
United Therapeutics Corporation's stock is valued at $261.70 at 00:22 EST, below its 52-week high of $283.09 and way higher than its 52-week low of $158.38.
4. Ultrapar Participacoes S.A. (UGP)
20% sales growth and 9.61% return on equity
Ultrapar Participações S.A. engages in the gas distribution, fuel distribution, chemicals, storage, and drugstores businesses primarily in Brazil, Mexico, Uruguay, Venezuela, other Latin American countries, the United States, Canada, the Far East, Europe, and internationally. Its Gas Distribution segment distributes liquefied petroleum gas to residential, commercial, and industrial consumers primarily in the South, Southeast, and Northeast regions of Brazil. The company's Fuel Distribution segment distributes and markets gasoline, ethanol, diesel, fuel oil, kerosene, natural gas for vehicles, and lubricants; operates convenience stores; and offers lubricant-changing and automotive specialized services. Its Chemicals segment produces ethylene oxide and its derivatives, and fatty alcohols that are raw materials used in the home and personal care, agrochemical, paints, varnishes, and other industries. The company's Storage segment operates liquid bulk terminals primarily in the Southeast and Northeast regions of Brazil. Its Drugstores segment trades in pharmaceutical, hygiene, and beauty products through its own drugstore chain in the North, Northeast, and Southeast regions of Brazil. As of December 31, 2020, the company operated through 7,107 Ipiranga service stations and 1,804 AmPm convenience stores; 1,172 Jet Oil franchises; 405 Extrafarma drugstores and 3 distribution centers; and 6 Ultracargo terminals with storage capacity of 838 thousand cubic meters. It also operates Abastece AÃ, a digital payments app; and offers Km de Vantagens, a loyalty program. The company was founded in 1937 and is headquartered in São Paulo, Brazil.
Earnings per Share
Ultrapar Participacoes S.A.'s trailing twelve-month EPS is $0.17.
PE Ratio
Ultrapar Participacoes S.A.'s trailing 12-month price-earnings ratio is 14.76. The purchaser of the shares is therefore investing $14.76 per dollar in annual earnings.
For the 12 trailing months, the company's return-on-equity, which is a measure of the business' profitability relative to shareholders' equity, was 9.61%.5. Novo Nordisk A/S (NVO)
11.6% sales growth and 72.19% return on equity
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Earnings Per Share
As for profitability, Novo Nordisk A/S has a trailing twelve months EPS of $2.92.
PE Ratio
Novo Nordisk A/S has a trailing twelve months price to earnings ratio of 47.6. Meaning, the purchaser of the share is investing $47.6 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 72.19%.6. Stantec (STN)
8.5% sales growth and 9.03% return on equity
Stantec Inc. offers professional consulting services for infrastructure and facilities across Canada and the United States. Consulting services include engineering, architectural, interior design and landscape architecture. Surveying, environmental sciences, project administration, economics, and management. The company also provides services in water, transport, and public works, transportation planning, traffic engineering, resource assessment, mining development, reclamation and hydrology services as well as geotechnical, infrastructure and urban planning services. The company also offers structural, mechanical and electrical engineering, as well as plumbing and hydraulics services. The company provides services in the areas of urban regeneration, infrastructure and education. It also serves tourism and leisure sectors as well as commercial and residential offices. Stantec Inc. was previously known as Stanley Technology Group Inc. Stantec Inc. was established in 1954. It is located in Edmonton, Canada.
Earnings Per Share
As for profitability, Stantec has a trailing twelve months EPS of $1.28.
PE Ratio
Stantec has a trailing twelve months price to earnings ratio of 40.41. Meaning, the purchaser of the share is investing $40.41 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.03%.Moving Average
Stantec's value is greater than its moving average 50 days of $49.04, and higher than its moving average 200 days of $47.20.Growth Estimates Quarters
The company's growth estimates for the current quarter and the next is 17.8% and 19.1%, respectively.7. A10 Networks (ATEN)
7.2% sales growth and 64.13% return on equity
A10 Networks, Inc. provides networking solutions in the United States, Japan, other Asia Pacific, and EMEA countries. The company offers Thunder Application Delivery Controller (ADC) that provides advanced server load balancing; Lightning ADC, a cloud-native software-as-a-service platform to boost the delivery and security of applications and micro services; and Thunder Carrier Grade Networking product, which offers standards-compliant address and protocol translation services for service provider networks. It also provides Thunder Threat Protection System (TPS) for the protection of networks and server resources against massive distributed denial of service attacks; Thunder Secure Sockets Layer (SSL) Insight solution that decrypts SSL-encrypted traffic and forwards it to a third-party security device for deep packet inspection; and Thunder Convergent Firewall, which addresses various critical security capabilities in one package by consolidating various security and networking functions in a single appliance. In addition, the company offers intelligent management and automation tools comprising harmony controller that provides intelligent management, automation, and analytics for secure application delivery in multi-cloud environment; and aGalaxy TPS, a multi-device network management solution. The company delivers its solutions on optimized hardware appliances, bare metal software, containerized software, virtual appliances, and cloud-native software. It serves cloud providers, service providers, government organizations, and enterprises in the telecommunications, technology, industrial, retail, government, financial, gaming, and education industries. The company markets its products through sales organizations, as well as distribution channel partners, including distributors, value added resellers, and system integrators. A10 Networks, Inc. was incorporated in 2004 and is headquartered in San Jose, California.
Earnings per Share
A10 Networks' trailing twelve-month EPS is $0.25.
PE Ratio
A10 Networks' trailing 12-month price-to-earnings ratio is 63.37. The purchaser of the shares is therefore investing $63.37 per dollar in annual earnings.
For the 12 trailing months, the company's return-on-equity, which is a measure of the profitability and shareholder equity for a business, was 64.13%.